The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor
Benjamin Adam Samuels,Katherine M. Nautiyal,Andrew C. Kruegel,Marjorie R Levinstein,Valerie M. Magalong,Madalee M. Gassaway,Steven G. Grinnell,Jaena Han,Michael Ansonoff,John E. Pintar,Jonathan A. Javitch,Dalibor Sames,René Hen +12 more
Reads0
Chats0
TLDR
Interestingly, while tianeptine also produces many opiate-like behavioral effects such as analgesia and reward, it does not lead to tolerance or withdrawal, which points to the possibility that MOR and its downstream signaling cascades may be novel targets for antidepressant drug development.About:
This article is published in Neuropsychopharmacology.The article was published on 2017-03-17 and is currently open access. It has received 80 citations till now. The article focuses on the topics: Tianeptine & Antidepressant.read more
Citations
More filters
Journal ArticleDOI
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
Nolan R. Williams,Boris D. Heifets,Christine Blasey,Keith Sudheimer,Jaspreet Pannu,Heather Pankow,Jessica Hawkins,Justin Birnbaum,David M. Lyons,Carolyn I. Rodriguez,Alan F. Schatzberg +10 more
TL;DR: The findings suggest that ketamine's acute antidepressant effect requires opioid system activation, and the dissociative effects of ketamine are not mediated by the opioid system, and they do not appear sufficient without the opioid effect to produce the acute antidepressant effects ofketamine in adults with treatment-resistant depression.
Journal ArticleDOI
Treatment resistant depression: A multi-scale, systems biology approach.
Huda Akil,Joshua A. Gordon,René Hen,Jonathan A. Javitch,Helen S. Mayberg,Bruce S. McEwen,Michael J. Meaney,Eric J. Nestler +7 more
TL;DR: A multi‐scale framework for fundamental research on depression is proposed, aimed at identifying the brain circuits that are dysfunctional in several animal models of depression as well the changes in gene expression that are associated with these models.
Journal ArticleDOI
The role of 5-HT receptors in depression
TL;DR: The role of serotonin in three distinct hypotheses that have been proposed over the last several decades to explain the pathophysiology of depression are revisited: the monoamine, neurotrophic, and neurogenic hypotheses.
Journal ArticleDOI
Toward Circuit Mechanisms of Pathophysiology in Depression.
Timothy Spellman,Conor Liston +1 more
TL;DR: Functional neuroimaging studies in humans have included largely task-oriented experiments that have identified brain regions differentially activated during processing of affective stimuli, and resting-state functional MRI experiments, which have identifiedbrain-wide networks altered in depressive states.
Journal ArticleDOI
Brain mechanisms mediating effects of stress on reward sensitivity.
Maria Ironside,Poornima Kumar,Poornima Kumar,Min Su Kang,Diego A. Pizzagalli,Diego A. Pizzagalli +5 more
TL;DR: Together, this cross-species confluence has enriched the understanding of stress-reward links but also highlighted the role of neuropeptides and opioid receptors in such effects, and thereby identified novel targets for stress-related neuropsychiatric disorders.
References
More filters
Journal ArticleDOI
Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants
Luca Santarelli,Michael Saxe,Cornelius Gross,Alexandre Surget,Fortunato Battaglia,Stephanie C. Dulawa,Noelia V. Weisstaub,James T. Lee,Ronald S. Duman,Ottavio Arancio,Catherine Belzung,René Hen +11 more
TL;DR: It is shown that disrupting antidepressant-induced neurogenesis blocks behavioral responses to antidepressants, suggesting that the behavioral effects of chronic antidepressants may be mediated by the stimulation of neuroGenesis in the hippocampus.
Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
TL;DR: The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.
Journal Article
Behavioral despair in mice: a primary screening test for antidepressants
Porsolt Rd,Bertin A,Jalfre M +2 more
TL;DR: The mouse procedure is more rapid and less costly than that with rats and is thus more suitable for the primary screening of antidepressant drugs, suggesting that the procedure is selectively sensitive to antidepressant treatments.
Journal ArticleDOI
Antidepressant effects of ketamine in depressed patients
Robert M. Berman,Angela Cappiello,Amit Anand,Amit Anand,Dan A. Oren,Dan A. Oren,George R. Heninger,Dennis S. Charney,Dennis S. Charney,John H. Krystal,John H. Krystal +10 more
TL;DR: A first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression suggests a potential role for NMDA receptor-modulating drugs in the treatment of depression.
Journal ArticleDOI
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
Carlos A. Zarate,Jaskaran Singh,Paul J. Carlson,Nancy E. Brutsche,Rezvan Ameli,David A. Luckenbaugh,Dennis S. Charney,Husseini K. Manji +7 more
TL;DR: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.